salt forms of semaglutide An Update on the Status Compounding Chancy Drugs offers semaglutide and

ACHIEVE-3 is a 52-week randomized, open-label trial including 1698 participants across the US, Argentina, China, Japan, Mexico, and Puerto Rico

Holmes says

Given the theoretical risk, Semaglutide should be avoided in those with a personal or family history of medullary thyroid carcinoma

These reports raise questions but do not provide strong proof

Severe gastrointestinal adverse effects (persistent vomiting or diarrhoea) can lead to dehydration and, in susceptible individuals, acute kidney injury

Due to progressive weight gain (137 kg, BMI 54.9 kg/m 2 , WC 140 cm and WHR 1.0.) despite non-pharmacological interventions with the support of a dietician, kinesiologist and psychologist, treatment with semaglutide was introduced